[1] 刘玉萍, 刘烨, 邱小玉. 新型降糖药达格列净的临床研究进展[J]. 中国医院药学杂志, 2019, 39(18): 1896-1899. [2] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1): 4-67. [3] 涂威, 陈静, 李亚玲. 钠-葡萄糖共转运蛋白2抑制剂导致正常血糖酮症酸中毒2例报道[J]. 华中科技大学学报(医学版), 2018, 47(4): 496-498. [4] FDA. Drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections[EB/OL]. (2015- 12-04)[2019-02-14]. http://www.fda.gov/Drugs/DrugSafety/ ucm475463.htm. [5] 段蓉, 李正翔. 基于openFDA对达格列净上市后不良反应的分析研究[J]. 中国医院药学杂志, 2018, 38(22): 2360-2362. [6] 芦志伟, 赵振宇, 李继彬. 22例钠-葡萄糖协同转运蛋白2抑制剂致酮症酸中毒的文献分析[J]. 中国医院药学杂志, 2019, 39(3): 69-73. [7] Puchalska P, Crawford P A.Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics[J]. Cell Metabolism, 2017, 25(2): 262-284. [8] Akram M.A Focused Review of the Role of Ketone Bodies in Health and Disease[J]. Journal of Medicinal Food, 2013, 16(11): 965-967. [9] Handelsman Y, Henry RR, Bloomgarden ZT, et al.American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis[J]. Endocr Pract, 2016, 22(6): 753-762. [10] 邢影, 姬秋和. 钠-葡萄糖共转运蛋白2抑制剂与酮体或酮症酸中毒的关系[J]. 中华糖尿病杂志, 2018, 10(2): 107-110. [11] 严颐丹, 施芳红. SGLT2抑制剂引起酮症酸中毒的机制及处理[J]. 中国医院药学杂志, 2018, 38(14): 1563-1565. [12] 刘敏, 苏娜, 徐珽. 钠-葡萄糖共转运蛋白2抑制剂引发糖尿病酮症酸中毒机制的研究进展[J]. 中国医院药学杂志, 2018, 38(3): 330-333. [13] Goldenberg RM, Berard LD, Cheng AYY, et al. SGLT2 Inhibitor- associated Diabetic Ketoacidosis: Clinical Review and Recom- mendations for Prevention and Diagnosis[J]. Clinical Therapeu- tics, 2016, 38(12): 2654-2664.e1. [14] Peters AL, Buschur EO, Buse JB, et al.Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium- Glucose Cotransporter 2 Inhibition[J]. Diabetes care, 2015, 38(9): 1687-1693. [15] Blau JE, Tella SH, Taylor SI, et al.Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data[J]. Diabetes Metab Res Rev, 2017,33(8): e2924. [16] EMA. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes[EB/OL]. (2016-02-26) [2019-02-19] https://www.ema.europa.eu/en/news/ema-confirms- recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors- diabetes. |